CCM
CRNX icon

CAAS Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

CAAS Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-166,317
Closed -$3.13M – 982
2021
Q2 		$3.13M Buy
+166,317
New +$2.92M 0.05% 318
2020
Q4 		– Sell
-35,792
Closed -$561K – 842
2020
Q3 		$561K Sell
35,792
-81,622
-70% -$1.25M 0.01% 383
2020
Q2 		$2.06M Buy
+117,414
New +$2M 0.07% 205

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAAS Capital Management's CRNX Position: Q3 2021 in Review

CAAS Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2021, closing a stake of 166,317 shares — an estimated $3.13M sold.

CAAS Capital Management first reported a position in CRNX in Q2 2020 and held it in 3 quarters. The position peaked at $3.13M in Q2 2021. 94 funds tracked by Wall St. Rank hold CRNX as of Q3 2021.

  • CAAS Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 166,317 Crinetics Pharmaceuticals shares in Q3 2021, an estimated $3.13M.
  • CAAS Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • CAAS Capital Management's Crinetics Pharmaceuticals position peaked at $3.13M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.